The history of Viagra presents a challenging picture for shareholders. While the initial release generated substantial profits, the end of its exclusive rights opened the door to cheaper alternatives, dramatically diminishing sales. This presents a specific risk for pharmaceutical companies banking on related blockbuster offerings, suggesting that

The story of Viagra, and its creator copyright, presents a intriguing case study for investors. Originally a blockbuster drug, yielding billions in income, its intellectual property lapse created a wave of lower-priced alternatives , significantly diminishing its dominance. While some firms may try to capitalize on related treatments , the present